非小细胞肺癌治疗中胸腔积液、血液表皮生长因子受体基因突变检测的价值  

Value of Pleural Fluid and Blood Epidermal Growth Factor Receptor Gene Mutation Detection in Non-Small Cell Lung Cancer Treatment

作　　者：张昌志 余倩[1] 王霄 彭春红[1] Zhang Changzhi;Yu Qian;Wang Xiao;Peng Chunhong(Department of Respiratory and Critical Care Medicine,Guizhou Provincial People's Hospital,Guiyang 550002,Guizhou Province,China)

机构地区：[1]贵州省人民医院呼吸与危重症医学科,贵州贵阳550002

出　　处：《中国社区医师》2024年第6期128-130,共3页Chinese Community Doctors

摘　　要：目的:分析非小细胞肺癌(NSCLC)治疗中实施胸腔积液、血液表皮生长因子受体(EGFR)基因突变检测的价值。方法:选取2022年1—12月于贵州省人民医院呼吸与危重症医学科治疗的42例NSCLC患者作为研究对象。检测患者血液、组织、胸腔积液3种标本EGFR基因突变状态,以肿瘤组织病理检查结果为“金标准”,分析3种标本检测的诊断效能。结果:42例患者中,共发生EGFR基因突变45.24%(19/42)。其中,L858R突变26.32%(5/19),19Del突变52.63%(10/19),G719X突变21.05%(4/19)。3种检查方式检测EGFR基因突变的灵敏度、特异度、准确度比较,差异无统计学意义(P>0.05)。结论:NSCLC治疗中实施胸腔积液、血液EGFR基因突变检测的价值确切,可以帮助医生更便捷地评估患者对于酪氨酸激酶抑制剂类药物的响应程度,预测治疗效果,从而指导治疗方案的制定和调整,为临床治疗提供依据。Objective:To analyze the value of epidermal growth factor receptor(EGFR)gene mutation detection in pleural effusion and blood during non-small cell lung cancer(NSCLC)treatment.Methods:A total of 42 patients with NSCLC who were treated in Department of Respiratory and Critical Care Medicine of Guizhou Provincial People's Hospital from January 2022 to December 2022 were selected as the study subjects.The EGFR gene mutation status in three types of specimens(blood,tissue and pleural effusion)was detected.The results of tumor histopathological examination were used as the golden standard,and the diagnostic efficiency of the detection using three types of specimens was analyzed.Results:Among the 42 patients,19 cases had EGFR gene mutations,accounting for 45.24%.Among them,there were 5 cases with L858R mutations(26.32%),10 cases with 19Del mutations(52.63%)and 4 cases with G719X mutations(21.05%).There was no significant difference in the sensitivity,specificity and accuracy of three examination methods for detecting EGFR gene mutations(P>0.05).Conclusion:The detection of EGFR gene mutation in pleural effusion and blood had definite value in NSCLC treatment,and can help doctors assess the response of patients to tyrosine kinase inhibitors in a more convenient manner,predict the treatment effect,so as to guide the formulation and modification of treatment regimens,and provide a basis for clinical treatment.

关 键 词：非小细胞肺癌 胸腔积液 血液 表皮生长因子受体 基因突变检测 

分 类 号：R446[医药卫生—诊断学]